Clinical Trial Update: MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of MT1013 Injection for secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• MT1013 Injection (MT1013)

Snippet

Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Conditions: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Phase 2 | Status: COMPLETED